SCHEMBL906308

SCHEMBL906308

NCC1C2CC3CC(C2)CC1C3

nearest known ligand 0.45

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.44
CYP2C9 P11712 1/20 0.38
GRIN2D O15399 2/20 0.33
GRIN3B O60391 2/20 0.33
GRIN1 Q05586 2/20 0.33
GRIN2A Q12879 2/20 0.33
GRIN2B Q13224 2/20 0.33
GRIN2C Q14957 2/20 0.33
GRIN3A Q8TCU5 2/20 0.33
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CXCR3 P49682 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2386838 0.97 HSD11B1 (0.42) HSD11B1CYP2C9GRIN2DGRIN3BGRIN1
SCHEMBL23451146 0.85 HSD11B1 (0.32) HSD11B1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL8148768 0.83
SCHEMBL21425644 0.80 HSD11B1 (0.35) HSD11B1CYP2C9
SCHEMBL22416817 0.78 HSD11B1 (0.33) HSD11B1
SCHEMBL1603764 0.77 HSD11B1 (0.41) HSD11B1CYP2C9GRIN2DGRIN3BGRIN1
SCHEMBL21650459 0.75 HSD11B1 (0.44) HSD11B1CYP2C9CXCR3
Hydrochloric Acid SCHEMBL7527143 0.75 HSD11B1 (0.39) HSD11B1CYP2C9GRIN2DGRIN3BGRIN1
SCHEMBL23790989 0.73 CYP2C9 (0.36) HSD11B1CYP2C9GRIN2DGRIN3BGRIN1
SCHEMBL24245369 0.73 CYP2C9 (0.36) HSD11B1CYP2C9GRIN2DGRIN3BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004045534-A2 CHROMAN DERIVATIVES FOR THE REDUCTION OF INFLAMMATION SYMPTOMS GALILEO PHARMACEUTICALS, INC. (US) 2004-06-03 WO claimed
US-20040097433-A1 Chroman derivatives for the reduction of inflammation symptoms MONSANTO TECHNOLOGY LLC 2004-05-20 US claimed
US-5932566-A Ansamycin derivatives as antioncogene and anticancer agents PFIZER INC. (US) 1999-08-03 US claimed
EP-0706516-A1 ANSAMYCIN DERIVATIVES AS ANTIONCOGENE AND ANTICANCER AGENTS PFIZER INC. (US) 1996-04-17 EP claimed
WO-1995001342-A1 ANSAMYCIN DERIVATIVES AS ANTIONCOGENE AND ANTICANCER AGENTS PFIZER INC. (US) 1995-01-12 WO claimed
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS SERVIER LAB (FR) 2026-01-01 US disclosed
EP-4551566-A1 NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS Les Laboratoires Servier (FR) 2025-05-14 EP disclosed
CN-119816491-A New spirocyclohexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors 法国施维雅药厂 2025-04-11 CN disclosed
WO-2024238396-A1 NMDA LIGAND CONJUGATED COMPOUNDS AND USES THEREOF ADARX PHARMACEUTICALS, INC. (US) 2024-11-21 WO disclosed
CN-118963059-A Photoresist composition, coated substrate comprising photoresist composition, and method of forming electronic device 罗门哈斯电子材料有限责任公司 2024-11-15 CN disclosed
CN-106933030-B Photoresist composition, coated substrate comprising photoresist composition, and method of forming electronic device 罗门哈斯电子材料有限责任公司 2024-08-16 CN disclosed
US-11960206-B2 Photoresist composition, coated substrate including the photoresist composition, and method of forming electronic device Rohm and Hass Electronic Materials LLC (US) 2024-04-16 US disclosed
US-5514683-A LIGANDS FKOR CHOLECYSTOKININ OR GASTRIN RECEPTORS JAMES BLACK FOUNDATION LIMITED (GB) 1996-05-07 US disclosed
EP-0706516-A1 ANSAMYCIN DERIVATIVES AS ANTIONCOGENE AND ANTICANCER AGENTS PFIZER INC. (US) 1996-04-17 EP disclosed
US-5488055-A ADMINISTERING GMP HOSPHODIESTERASE INHIBITORS FOR TREATMENT OF CONGESTIVE HEART FAILURE AND CARDIOVASCULAR DISORDERS SANOFI WINTHROP INC. (US) 1996-01-30 US disclosed
WO-1995001342-A1 ANSAMYCIN DERIVATIVES AS ANTIONCOGENE AND ANTICANCER AGENTS PFIZER INC. (US) 1995-01-12 WO disclosed
EP-0626942-A1 BICYCLO 2.2.2.]OCTANE DERIVATIVES AS CHOLESTOCYSTOKININ INHIBITORS. BLACK JAMES FOUNDATION (GB) 1994-12-07 EP disclosed
WO-1993016982-A1 BICYCLO[2.2.2.]OCTANE DERIVATIVES AS CHOLESTOCYSTOKININ INHIBITORS JAMES BLACK FOUNDATION LIMITED (GB) 1993-09-02 WO disclosed
WO-1992020336-A2 NOVEL CHOLESTEROL LOWERING COMPOUNDS MERCK & CO., INC. (US) 1992-11-26 WO disclosed
EP-0512865-A2 Novel cholesterol lowering compounds MERCK & CO. INC. (US) 1992-11-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11960206-B2 Photoresist composition, coated substrate including the photoresist composition, and method of forming electronic device PPIG, PARG, EEF1G HSD11B1 3177/4885CYP2C9 397/4885GRIN2D 103/4885
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS BCL2, BCL2A1, BAX HSD11B1 135/4885CYP2C9 2339/4885GRIN2D 3869/4885
US-20040097433-A1 Chroman derivatives for the reduction of inflammation symptoms CCL2, MPO, MB HSD11B1 854/4885CYP2C9 589/4885GRIN2D 4310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.